COVID-19 in a Patient with X-Linked Agammaglobulinemia: A Case Report
Publicado en línea: 11 jul 2022
Páginas: 185 - 188
Recibido: 09 may 2020
Aceptado: 17 jun 2020
DOI: https://doi.org/10.2478/sjecr-2020-0062
Palabras clave
© 2021 Mahmoud Sadeghi-Haddad-Zavareh et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
X-linked agammaglobulinemia (XLA), characterized by a profound deficiency of B lymphocytes, is caused by mutations in the gene encoding Bruton tyrosine kinase (Btk).. XLA patients have a susceptibility to viral infections. In this report, we present a 45-year-old man with known XLA, with about a 2-week history of fever, chills, diarrhea and vomiting. He was diagnosed with COVID-19 infection, which was confirmed by a real-time reversetranscriptase- polymerase chain reaction. The antiviral drugs, antibiotics, and interferon-beta were administered to him. Unfortunately, the patient passed away after 5 days. During an epidemic of infectious diseases, the best strategy to overcome the potential challenges of treating XLA may be prevention. Early detection of biomarkers such as D-dimer and IL-6 might be more helpful for initiating more aggressive therapy and decreasing the duration of illness in these patients.